Target family: Ionotropic glutamate receptors (type: lgic)
Target: GluA3

Ligand: AMPA (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: aniracetam (Synthetic organic)
Interaction type: Allosteric modulator
Action: Positive
Ligand approved: yes
Primary target: no
Median affinity:  -

Ligand: argiotoxin (Natural product)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: ATPO (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: CX516 (Synthetic organic)
Interaction type: Allosteric modulator
Action: Positive
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: CX546 (Synthetic organic)
Interaction type: Allosteric modulator
Action: Positive
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: cyclothiazide (Synthetic organic)
Interaction type: Allosteric modulator
Action: Positive
Ligand approved: yes
Primary target: no
Median affinity: 4.860000133514404 pEC50
Reference (Journal): Novel AMPA receptor potentiators LY392098 and LY404187: effects on recombinant human AMPA receptors in vitro.
Published in: Neuropharmacology

Ligand: GYKI53655 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: GYKI53784 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: IDRA-21 (Synthetic organic)
Interaction type: Allosteric modulator
Action: Positive
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: (S)-5-fluorowillardiine (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: joro spider toxin (Natural product)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: LY392098 (Synthetic organic)
Interaction type: Allosteric modulator
Action: Positive
Ligand approved: no
Primary target: no
Median affinity: 5.71999979019165 pEC50
Reference (Journal): Novel AMPA receptor potentiators LY392098 and LY404187: effects on recombinant human AMPA receptors in vitro.
Published in: Neuropharmacology

Ligand: LY404187 (Synthetic organic)
Interaction type: Allosteric modulator
Action: Positive
Ligand approved: no
Primary target: no
Median affinity: 5.78000020980835 pEC50
Reference (Journal): Novel AMPA receptor potentiators LY392098 and LY404187: effects on recombinant human AMPA receptors in vitro.
Published in: Neuropharmacology

Ligand: LY503430 (Synthetic organic)
Interaction type: Allosteric modulator
Action: Positive
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: NBQX (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: piracetam (Synthetic organic)
Interaction type: Allosteric modulator
Action: Positive
Ligand approved: yes
Approval source: UK (1992)
Primary target: no
Median affinity:  -

Ligand: S18986 (Synthetic organic)
Interaction type: Allosteric modulator
Action: Positive
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: [3H]AMPA (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -

Ligand: [3H]CNQX (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -

Ligand: tezampanel (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  -